Literature DB >> 14960593

Identification of species-specific determinants of the action of the antagonist capsazepine and the agonist PPAHV on TRPV1.

Elsa Phillips1, Alison Reeve, Stuart Bevan, Peter McIntyre.   

Abstract

The vanilloid receptor 1 (VR1 or TRPV1) ion channel is activated by noxious heat, low pH and by a variety of vanilloid-related compounds. The antagonist, capsazepine is more effective at inhibiting the human TRPV1 response to pH 5.5 than the rat TRPV1 response to this stimulus. Mutation of rat TRPV1 at three positions in the S3 to S4 region, to the corresponding human amino acid residues I514M, V518L, and M547L decreased the IC(50) values for capsazepine inhibition of the pH 5.5 response from >10,000 nm to 924 +/- 241 nm in [Ca(2+)](i) assays and increased capsazepine inhibition of the capsaicin response to levels seen for human TRPV1. We have previously noted that phorbol 12-phenylacetate 13-acetate 20-homovanillate (PPAHV) is a strong agonist of rat TRPV1 but not human TRPV1 in [Ca(2+)](i) assays (1). Mutation of methionine 547 in S4 of rat TRPV1 to leucine, found in human TRPV1 (M547L), reduced the ability of PPAHV to activate TRPV1 by approximately 20-fold. The reciprocal mutation of human TRPV1 (L547M) enabled the human receptor to respond to PPAHV. These mutations did not significantly affect the agonist activity of capsaicin, resiniferatoxin (RTX) or olvanil in [Ca(2+)](i) assays. Introducing the equivalent mutation into guinea pig TRPV1 (L549M) increased the agonist potency of PPAHV by > 10-fold in the [Ca(2+)](i) assay and increased the amplitude of the evoked current. The rat M547L mutation reduced the affinity of RTX binding. Thus, amino acids within the S2-S4 region are important sites of agonist and antagonist interaction with TRPV1.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14960593     DOI: 10.1074/jbc.M313328200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  29 in total

1.  Human embryonic stem cell-derived neurons as a tool for studying neuroprotection and neurodegeneration.

Authors:  Giles E Hardingham; Rickie Patani; Paul Baxter; David J Wyllie; Siddharthan Chandran
Journal:  Mol Neurobiol       Date:  2010-04-30       Impact factor: 5.590

2.  Structural insight into tetrameric hTRPV1 from homology modeling, molecular docking, molecular dynamics simulation, virtual screening, and bioassay validations.

Authors:  Zhiwei Feng; Larry V Pearce; Xiaomeng Xu; Xiaole Yang; Peng Yang; Peter M Blumberg; Xiang-Qun Xie
Journal:  J Chem Inf Model       Date:  2015-02-18       Impact factor: 4.956

3.  Structure determination of the human TRPV1 ankyrin-repeat domain under nonreducing conditions.

Authors:  Miki Tanaka; Kaori Hayakawa; Nozomi Ogawa; Tatsuki Kurokawa; Kenichi Kitanishi; Kenji Ite; Toshitaka Matsui; Yasuo Mori; Masaki Unno
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2020-03-02       Impact factor: 1.056

4.  Distinct modulations of human capsaicin receptor by protons and magnesium through different domains.

Authors:  Shu Wang; Kinning Poon; Robert E Oswald; Huai-hu Chuang
Journal:  J Biol Chem       Date:  2010-02-09       Impact factor: 5.157

5.  Zinc inactivates melastatin transient receptor potential 2 channels via the outer pore.

Authors:  Wei Yang; Paul T Manna; Jie Zou; Jianhong Luo; David J Beech; Asipu Sivaprasadarao; Lin-Hua Jiang
Journal:  J Biol Chem       Date:  2011-05-20       Impact factor: 5.157

6.  Effect of chirality and lipophilicity in the functional activity of evodiamine and its analogues at TRPV1 channels.

Authors:  Luciano De Petrocellis; Aniello Schiano Moriello; Gabriele Fontana; Alessandro Sacchetti; Daniele Passarella; Giovanni Appendino; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

Review 7.  Structure and function of TRPV1.

Authors:  Makoto Tominaga; Tomoko Tominaga
Journal:  Pflugers Arch       Date:  2005-06-22       Impact factor: 3.657

8.  Functional characterisation of the S512Y mutant vanilloid human TRPV1 receptor.

Authors:  Kathy G Sutton; Elizabeth M Garrett; A Richard Rutter; Timothy P Bonnert; Wolfgang Jarolimek; Guy R Seabrook
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

9.  Targeting the transient receptor potential vanilloid type 1 (TRPV1) assembly domain attenuates inflammation-induced hypersensitivity.

Authors:  Robyn Flynn; Kevin Chapman; Mircea Iftinca; Reem Aboushousha; Diego Varela; Christophe Altier
Journal:  J Biol Chem       Date:  2014-05-07       Impact factor: 5.157

Review 10.  High-resolution views of TRPV1 and their implications for the TRP channel superfamily.

Authors:  Ute A Hellmich; Rachelle Gaudet
Journal:  Handb Exp Pharmacol       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.